Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Alectinib (Alecensaro) for Non- Small Cell Lung Cancer (with brain metastases)
(Notification to Implement Issued as of May 19, 2017)

Osimertinib (Tagrisso) for Non- Small Cell Lung Cancer
(Notification to Implement Issued as of May 19, 2017)

Midostaurin (Brand Name: TBD) for Acute Myeloid Leukemia
(Pending Submission as of May 12, 2017)

 

 

Find a Drug Review